ASR-3001

Last updated

ASR-3001
5-MeO-ALiPT structure.png
Clinical data
Other namesASR3001; 5-MeO-iPALT; 5-MeO-ALiPT; 5-Methoxy-N-allyl-N-isopropyltryptamine
Routes of
administration 		Oral [1]
Drug class Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action ≤15 minutes [1] [2] [3]
Duration of action "Short" [1]
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChem CID
Chemical and physical data
Formula C17H24N2O
Molar mass 272.392 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C=C(C=C2)OC)CC=C
  • InChI=1S/C17H24N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h5-7,11-13,18H,1,8-10H2,2-4H3
  • Key:MRWWDVFDOFUYKB-UHFFFAOYSA-N

ASR-3001, also known as 5-methoxy-N-allyl-N-isopropyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders. [4] [1] [2] [3] [5] It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT. [5]

Contents

The drug acts as a non-selective agonist of the serotonin receptors. [5] This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described. [5] Its EC50 Tooltip half-maximal effective concentration values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor. [5] The drug was also a very weak serotonin reuptake inhibitor (IC50 Tooltip half-maximal inhibitory concentration = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake. [5] It also showed little or no activity at various other sites. [5]

ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory involvement". [1] [2] [3] These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience including visuals. [1] Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes, and its duration is described only as "short". [1] [2] [3]

ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI). [4] [1] It was first described by 2023 and was patented the same year. [1] [5] As of early 2025, ASR-3001 is in the preclinical research stage of development. [4] [6]

Other related analogues of ASR-3001 include ASR-3002 (2-Me-iPALT), ASR-3003 (iPALT), and ASR-3004 (PALT), among others. [5]

See also

References

  1. 1 2 3 4 5 6 7 8 9 Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025.
  2. 1 2 3 4 Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025.
  3. 1 2 3 4 Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025.
  4. 1 2 3 "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". Synapse. 16 April 2025. Retrieved 19 April 2025.
  5. 1 2 3 4 5 6 7 8 9 WOpatent 2023034645A2,Paul Daley; Nicholas Cozzi& Wyeth Baillie Callaway,"Asymmetric allyl tryptamines",published 9 March 2023, assigned to Alexander Shulgin Research Institute
  6. ↑ Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.